|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Mar 30, 2007. Selling,
General and Administrative Expenses (SG&A)
SG&A expenses decreased by 8% to $417.1 million in 2006
from $452.7 million in 2005. The decrease primarily
reflects lower net SG&A expenses recorded in relation to
Tysabri, as explained further below, along with reduced
costs in the rest of the business, due to ongoing financial
discipline.
In any period where an operating loss has been incurred on sales
of Tysabri, as was the case for both 2006 and 2005, we
record, within SG&A expenses, our Tysabri-related
SG&A less our share of the gross profit on in-market sales
of Tysabri. Included within SG&A expenses is
$79.1 million (2005: $103.2 million) of net SG&A
expenses in relation to Tysabri, which comprised:
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Selling,
General and Administrative Expenses (SG&A)
SG&A expenses were $363.1 million in 2006, compared to
$358.4 million in 2005, and included $75.0 million
(2005: $84.7 million) in relation to Tysabri. The
increase in total SG&A expenses reflects the expensing of
share-based compensation of $28.8 million in 2006 (2005:
$Nil), offset by decreased expenses in relation to Tysabri
and also due to ongoing financial discipline. The decrease
in SG&A expenses related to Tysabri reflects the
impact of the temporary suspension of Tysabri in 2005,
the re-launch of Tysabri in the United States in 2006,
and the launch of Tysabri in the European Union in 2006,
partially offset by the expensing of shared-based compensation
of $2.5 million (2005: $Nil).
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Selling, General and Administrative
Expenses (SG&A)
SG&A expenses increased by 15% to $452.7 million for
2005 from $393.8 million for 2004. SG&A expenses
include exceptional operating income of $3.3 million in
2005 (2004: $35.7 million expense). Excluding exceptional
items, SG&A expenses increased from $358.1 million in
2004 to $456.0 million in 2005. The increase primarily
reflects the losses incurred on sales of Tysabri prior to
its suspension from market as explained further below, the costs
of maintaining the Tysabri commercial infrastructure in
place for the full year 2005 in anticipation of its potential
return to market, and the cost of launching Prialt during
2005, offset by reduced costs in the rest of the business.
The FDA granted accelerated approval of Tysabri in late
November 2004 for the treatment of patients in the United States
with all forms of relapsing remitting MS. Our collaboration with
Biogen Idec for Tysabri is a
jointly-controlled operation.
In any period where a net loss has been incurred on sales of
Tysabri, we record our share of the net loss along with
our directly incurred expenses within operating expenses. We
incurred $99.1 million in 2005 (2004: $50.7 million)
of SG&A expenses in relation to Tysabri, of which
$84.7 million (2004: $52.8 million) relates to the
costs of commercialisation activities and $14.4 million
(2004: $2.1 million gain) reflects losses on sales of
Tysabri. The losses on sale are based on in-market
sales of $11.0 million (2004: $6.4 million) (net of
returns of $18.5 million (2004: $Nil)) associated with the
voluntary suspension of Tysabri), and includes
$14.0 million (2004: $Nil) for the write-off of Tysabri
inventory. The marketing and clinical dosing of Tysabri
was voluntarily suspended in February 2005. On
7-8 March 2006, the PCNS Advisory Committee reviewed and
voted unanimously to recommend that Tysabri be
reintroduced as a treatment for relapsing forms of MS. On
21 March 2006, we and Biogen Idec were informed by the FDA
that the agency would extend its regulatory review of Tysabri
by up to 90 days in order to complete a full review of
the Tysabri risk management plan. Under the revised
timeline, we anticipate an action from the FDA about the
reintroduction of Tysabri as a treatment for relapsing
forms of MS on or before 28 June 2006.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Selling,
General and Administrative Expenses (SG&A)
SG&A expenses were $337.3 million in 2004 compared to
$384.2 million in 2003. The decrease of 12% reflects the
overall reduction in our activities as a result of the business
and product divestments in both 2004 and 2003, offset by the
costs of certain commercialization activities related to the
launch of Tysabri. We incurred $52.3 million of
launch costs in 2004 on Tysabri.
This excerpt taken from the ELN 6-K filed Apr 11, 2005. Selling, General and Administrative Expenses (“SG&A”) SG&A expenses, after exceptional items, decreased by 60% to $410.8 million for 2004 from $1,016.3 million for 2003. The decrease was 20% before exceptional items of $35.7 million for 2004 and $546.0 million for 2003, reflecting the overall reduction in our activities as a result of the business and product divestments in both 2004 and 2003, offset by the costs of certain commercialisation activities related to the launch of Tysabri. We incurred approximately $35.0 million of launch costs in the fourth quarter of 2004 on Tysabri. | EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
